Research Papers:

A novel approach to inoperable or recurrent rectal cancer by chemoembolization. A new arrow in our quiver?

Roberto Bini _, Simone Comelli, Renzo Leli, Giacomo Paolo Vaudano, Daniele Savio, Tiziana Viora and Alfredo Addeo

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:45275-45282. https://doi.org/10.18632/oncotarget.9940

Metrics: PDF 2296 views  |   HTML 1867 views  |   ?  


Roberto Bini1, Simone Comelli2, Renzo Leli1, Giacomo Paolo Vaudano2, Daniele Savio2, Tiziana Viora1, Alfredo Addeo3

1General Surgery Department, SG Bosco Hospital, Turin, Italy

2Interventional Radiology- Neuroradiology Department, SG Bosco Hospital, Turin, Italy

3Oncology Department, Bristol Cancer Center, Bristol, UK

Correspondence to:

Roberto Bini, email: [email protected]

Keywords: debiri, rectal cancer, chemoembolization, cancer recurrence

Received: November 09, 2015     Accepted: May 20, 2016     Published: June 10, 2016


Purpose: Assess the feasibility, safety and efficacy of TACE with irinotecan loaded micro particles (debiri) for the treatment of locally advanced rectal cancer patients.

Results: We assessed the Edmonton Symptom Assessment System (ESAS). The tool is designed to assess nine common symptoms in cancer patients: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing and shortness of breath. The ESAS score was 7 in 10/12 (83%) patients before treatment and 6 in 2/12 (16.5%) patients. After treatment in 6/12 (50%) patients the score dropped to 3; 3/12 (33%) reported 4, 1/12 (8%) reported 2. All patients experienced local control disease with a degree of citoreduction; in 4 cases (33%) we observed outstanding responses with a dramatic reduction in the tumors size which led us to surgical radical resections.

Materials and methods: We run a prospective mono-institutional study where we recruited, 12 non- consecutive patients with histology confirmation of rectal cancer, inoperable and not treatable due to severe comorbidities, or pelvic recurrence/progression after curative treatment, chemotherapy, radiotherapy and/or surgery. Their performance status (PS) ECOG was 2-3 . Twelve patients (10 male and 2 female) with a median age 71 (range 56-89) were recruited in the study.

Conclusions: The study has met the primary endpoint and showed encouraging activity. Debiri could be a possible option for locally advanced/inoperable or recurred rectal cancer patients. Further trials are warranted to validate this methodic in early stages.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9940